# Phase IIB Study of Recombinant Novel Coronavirus Vaccine

> **NCT05293223** · PHASE2 · COMPLETED · sponsor: **Fundación Huésped** · enrollment: 88 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** Ad5-nCov

## Key facts

- **NCT ID:** NCT05293223
- **Lead sponsor:** Fundación Huésped
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-11-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-06-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293223, "Phase IIB Study of Recombinant Novel Coronavirus Vaccine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05293223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*